Monthly Archives: September 2014

Biothera to Present Late-Breaking Data from its Phase 2 Randomized Immunotherapy Trial in Non-Small Cell Lung Cancer at ESMO 2014

EAGAN, MN — September 28, 2014 — Biothera will present today results on its investigational immunotherapy Imprime PGG® in combination with standard of care frontline chemotherapy and bevacizumab in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC) at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid. The addition of Imprime PGG to standard of care carboplatin, paclitaxel and bevacizumab achieved...

Read More


Biothera to Present at European Society of Medical Oncology 2014 Congress

Late-Breaking Abstract on Non-Small Cell Lung Cancer Study Results Accepted EAGAN, MN — September 17, 2014 — Biothera announced today that new data and insights for Imprime PGG, the company’s investigational cancer immunotherapy drug, will be featured in three presentations, including a late-breaking abstract, at the European Society of Medical Oncology (ESMO) 2014 Congress on September 26-30 in Madrid. “We are excited to present cutting-edge...

Read More